Biotech Values

[DewDiligence]

Improving VA by >=15 letters is a common secondary endpoint in wet-AMD trials and it is what companies should be aiming to show, at least in treatment-naïve patients. I misspoke when I said this was the standard primary endpoint.

From a commercial standpoint, improving vision is a much stronger selling point than merely arresting vision loss in someone whose vision is already poor.